RE:RE:RE:No sellers I won't reply to NoShorts because he has a very low IQ and it's boring to talk to him. You on the other than are worth replying to;
Not all acquisions are worth the dilution ( although some are ). Look at what happened to DOC.v. Bought revenue used to be the big pump in the days of low rates. Not so much now. Also sometimes a need for more financing is hidden inside the news of the raise as many companies whose growth model is by acquisition do run out of funds due to high expenses associated with such strategy . Smart investors, meaning opposite to NoShorts ( or mainly institutional ones ) can see the difference between bought revenue and an acquisition that fits properly.
Cashflow, organic growth and profits matter most. Companies like CRH for example, or clinics , etc won't get the same multiple like high growth technology will fetch. There is a reason why WELL is not getting the multiples other companies in the space get.
Also you replied to my point like an insider.... lol .... I never said there is anything wrong with another raise .... I said judging by the behaviour of the stock in the past month, I suspect a possible raise could be on the horizon! What they do with the raised funds is another topic and I wouldn't comment until we see how the market reacts to it. Like I said before, once the Q4 numbers are out, organic growth, profitability and cashflow are known, we will see why the stock has moved the way it has. ( promo running leading to a raise or actual institutional investors buying the stock which will keep the stock at its current levels )
NoShort's tree planting funds won't move a stock that has 220 Million shares outstanding.